title: Imatinib in melanoma: a selective treatment option based on KIT mutation status?
authors.forename: Jürgen C
authors.initials: JC
authors.lastname: Becker
authors.forename: Eva B
authors.initials: EB
authors.lastname: Bröcker
authors.forename: Dirk
authors.initials: D
authors.lastname: Schadendorf
authors.forename: Selma
authors.initials: S
authors.lastname: Ugurel
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics; D009154:Mutation; D010879:Piperazines / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit